Smith Group Asset Management’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-661
Closed -$371K 175
2026
Q1
$371K Sell
661
-8
-1% -$5.13K 0.02% 150
2025
Q4
$453K Buy
669
+89
+15% +$60.6K 0.02% 139
2025
Q3
$371K Buy
+580
New +$352K 0.02% 148
2018
Q3
Sell
-211,975
Closed -$46.2M 439
2018
Q2
$46.2M Buy
211,975
+8,010
+4% +$1.65M 1.34% 19
2018
Q1
$39M Buy
203,965
+13,331
+7% +$2.46M 1.28% 24
2017
Q4
$29.8M Sell
190,634
-6,470
-3% -$1.02M 0.94% 31
2017
Q3
$30.6M Sell
197,104
-48,590
-20% -$7.68M 1.02% 31
2017
Q2
$39.7M Sell
245,694
-69,350
-22% -$11.3M 1.22% 23
2017
Q1
$48.7M Sell
315,044
-105,100
-25% -$14.5M 1.41% 15
2016
Q4
$49.3M Buy
420,144
+287,074
+216% +$32.8M 1.44% 20
2016
Q3
$15M Sell
133,070
-1,190
-0.9% -$125K 0.44% 69
2016
Q2
$12.5M Buy
+134,260
New +$11.5M 0.37% 81

Other funds holding IDXX

Smith Group Asset Management's IDXX Position: Q2 2026 in Review

Smith Group Asset Management sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 661 shares — an estimated $371K sold.

Smith Group Asset Management first reported a position in IDXX in Q2 2016 and held it in 12 quarters. The position peaked at $49.3M in Q4 2016. 773 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Smith Group Asset Management reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
  • Smith Group Asset Management sold 661 Idexx Laboratories shares in Q2 2026, an estimated $371K.
  • Smith Group Asset Management first reported a position in Idexx Laboratories in Q2 2016 and held it in 12 quarters.
  • Smith Group Asset Management's Idexx Laboratories position peaked at $49.3M in Q4 2016.
  • 773 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Smith Group Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.